Screening for Hematologic Disorders

8/17/2019 Screening for Hematologic Disorders

1/55

!

" #


2/55

$ % % &

" % " "%

'(


3/55

!


4/55


5/55

Phospholipids 80%SaturatedPhosphatidylcholine 60%UnsaturatedPhosphatidylcholine 25%Phosphatidylglycerol andPhosphatidylinositol 15%

Protein 12%

Neutral Lipids 8%


6/55

" # ( "#"

" ! # '((" )

" $ " # !


7/55

%


8/55

# " *+ " "


9/55

% ,' '

- ,- . & -

- (

- & "-


10/55

$ . ) &

' " ) ) ( & +

) " "( % + . '* ! ) /

% # ( & ) 0 1223


11/55

" % ! " ! #

$ % " $ " ! " ! # & '( ( $ ( ( ( ) ' ! * ' "

+ # (

% # ( & ) 0 1223


12/55

PREVENTION

!

TREATMENT

Prophylactic

PreVentilation

PostVentilation

EarlyRescue Late

Rescue

) ( 44 5 62 ( 5 1 % " 45 7 % " 44 583 %


13/55

&' ()"(* +, 9 "( % + " (

( % ( ! (

% (# " ( # % " ( %

" 0

% # ( & ) 0 1223


14/55

, "' ' - . /! #

" 0 0

1 ! , 1 - * 0$ " ! 2 3

$ 4 0 5)6$ - * - *

$17 ** $ " ! ’# **

8 ** **


15/55

* ) "#" %

* " %

- + . / 0

No clinically significant difference in outcome

between immediate administration of prophylacticsurfactant and administration at 10 min after birthafter a brief period of stabilization


16/55

↓↓↓↓

, 12 ↓↓↓↓ . $ !

, 1: ↓↓↓↓ /

, :2 ↓↓↓↓ %1

, 66

An ounce ofprevention isbetter than a

pound of cure !!

2 0

% # ( & ) 0 1223


17/55

Early surfactant with brief ventilation Vsselective surfactant and MV for pretermwith or at risk for RDS

' 0 %- ;- 0 - 0 9 (


18/55

7 / " ! (! 9 6 : 5

* ( # # # !( * % ( " ( $1

7 ! #! " ! (! 9 6 ( ; 5 / ( (( / !

( (% * $17


19/55

+

' 0 % "

9 ) ) )

) (

' ( " + 0% % % "" "

% " (


20/55

= + '' ! - (

" - > " ' .

- 2' ( > * (

! # ?


21/55

↓↓↓↓

, 12 ↓↓↓↓ . $ !

, ?7

↓↓↓↓ / 3 %1 , ?? ! 3 )

↓↓↓↓ ! 3 %2- , ?@ ! 1: )

% # ( & ) 0 1223


22/55

↓↓↓↓ / , 7

/$ !%2-

!

% # ( & ) 0 1223


23/55

. 01 &'* ,

↓↓↓↓ / , 12

↓↓↓↓ %1

, ?7 ↓↓↓↓

, 66 ↓↓↓↓ 4!

, 66

% # ( & ) 0 1223


24/55

( ) ) " ) ' " ) " "

A % " *+ " A % " + B/8 ; "


25/55

5 0

% " ) % (! ) &

* ( ) ( 0 % " " C & >" ( ) " 0 "( %

0 %

.

, ! 1 - ( & ( ) 3

@ 0 ,1


26/55

& ". .,

- - %

" , ( " - '(("

- ' ( " " - * % .& " . " "

A 9 , $ 3 A 0 0 5 33


27/55

--8-" +/"

& ") 8 (

?:"

: (*+ "

(

& "1? 1:-1 :"

? 1: (" "

& "88"

8 (" )

>"!( .9

2 ? 9


28/55

- 10C2-8 C2-8 CStorage

3/ 5 ml1.5 ml4 / 8 mlVial size

Bovine liquidPorcine lungBovine lungSource

Slowly warm toroom temp

Wait for 30min

Warm atroom temp

for 10minOr in hand

for 8 min

Gettingready

334Max. doses

5 cc/kg2.5 cc/kg4 cc/kgInitial doseYesYesYesTreatment

NoNoYesProphylaxis

NeosurfCurosurfSurvanta


29/55

. 0

( % # " " %# ) +

( # 0 ( )" % ) % 0 % ( # 0 % ( ( ( <

" (

% " 122@D?EF?:2-?:8


30/55

Implementation of surfactant treatmentduring CPAP (INSURE)

) ( ! * A8

6 03B * ! * ( C # ;0 (* ( *

7 ' " ** )1&.' ( # /!

(* ( (( ' A8

! D . @ $ 3 @ 3 3 3


31/55

6 .

*,, # " ; " ; "

0 " ) *,,

G


32/55

5 . 0

% ( (% + (

% "

"


33/55

7 2 .

,0 # %

( ( % % %

# % 0 % ) #

% # ( & ) 0 1223


34/55

" & ) + #

& - ( % " # F

- " + >" ( 62 (- % 1 >" ( # 7 %

- "# ?1 % ( % - . 5 2 11


35/55

2 .

& % I "

0 # " " " + (

A % % " ; #(( + "#


36/55

, 0 # "

& 9 " ( "( . % ( %

% # "

'(("


37/55

.

/"


38/55

"$ % %

' " ) ) 5 ?1:2 (

" )

)

A #* A 4 " 1 9 - 0 5 05


39/55

! "( (

"(

" ( % ( %

% " (

% ( %


40/55

. *+ ( % 0 % % (

# 5 68 0 9 % " # ) " . "

) #

(#

" ( ) " "( % % (


41/55

( " %

% " "( # 1@C13 0 9 J

''

"

( )" ( % ) ( 9 (

''

.


42/55

1990 2006

Exosurf Survanta Infasurf Curosurf1991 1998 1999

Surfaxin

Animal derived proteincontaining surfactants

In two trials of protein containing synthetic surfactants

compared to animal derived surfactant extract,no statistically different clinical differencesin death and chronic lung disease were noted.

Cochrane Database Syst Rev. 2008


43/55

% ( )

) ) " %9 &

' " % % 9 (

(# " ) !

E7 4 # . $ ( 8 0 0 9 -


44/55

# G C % " # "" " % ( ) "

% % " (

% "

,% # # % " # ( #< )

%


45/55

,% % " & "

) % % ) ;

% " % # " % #" ( # # "

% # ) " G

% ( - ) % "( ) " ( &

%


46/55

* " % # %

" % " # ( # # 0& 0% 1 8 ( 7 ( 0% )

& 0 + "# " (

%


47/55

%

,% ) % + # ) ( ( ( % 1

0 % 0 % " + " "( " % "

0 % " ( # '' #


48/55

+ .

8 . . *

.

% %9 9

%72 9 5 5


49/55

Thermoregulation Infection

Nutrition

R D S

Hostresponse

Ventilation

Supportivecare


50/55


51/55

U i i b bbl i i


52/55

Using microbubble test in gastric

aspirates for surfactant ( < 31 w) 5 " - -- ( A >"" ' '!( * F ; G 5 A >"" # (

! ' 55B ! / A ' '! ( *

* ( / ! ! #! A C( ! ' # ' B , 0 B

B * ( - : / %( *# ( B * ( - /

0 / %( ( *

9 @ $ A 0 3


53/55

9 /

/ * 0 # # % (-( %+ % " " )

% % :2 H % ? : H! ? H

:2 ( .9 ( (

1 ( & :22.

D' K & ?EE3 D?2@F??6-@

%


54/55

% . (

'( ) " ) ) ( & # #

(

(

< )

1228

.


55/55

*+ " " , ( ( 8: (

Documents

Screening for Hematologic Disorders